Your browser doesn't support javascript.
loading
A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
Li, Peng; Venkatachalam, Shobi; Ospina Cordona, Daniela; Wilson, Lorena; Kovacsovics, Tibor; Moser, Karen A; Miles, Rodney R; Beck, David B; George, Tracy; Tantravahi, Srinivas K.
Afiliação
  • Li P; Division of Hematopathology, Department of Pathology, University of Utah Health, Salt Lake City, UT.
  • Venkatachalam S; ARUP Laboratories, Salt Lake City, UT.
  • Ospina Cordona D; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; and.
  • Wilson L; National Human Genome Research Institute, Bethesda, MD.
  • Kovacsovics T; National Human Genome Research Institute, Bethesda, MD.
  • Moser KA; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; and.
  • Miles RR; Division of Hematopathology, Department of Pathology, University of Utah Health, Salt Lake City, UT.
  • Beck DB; ARUP Laboratories, Salt Lake City, UT.
  • George T; Division of Hematopathology, Department of Pathology, University of Utah Health, Salt Lake City, UT.
  • Tantravahi SK; ARUP Laboratories, Salt Lake City, UT.
Blood Adv ; 6(2): 405-409, 2022 01 25.
Article em En | MEDLINE | ID: mdl-34649277
ABSTRACT
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic mutations in UBA1 and is identified by a genotype-driven method. This condition affects unrelated men with adultonset inflammatory syndromes in association with hematologic manifestations of peripheral cytopenia and bone marrow myeloid dysplasia. Although bone marrow vacuolization restricted to myeloid and erythroid precursors has been identified in patients with VEXAS, the detailed clinical and histopathological features of peripheral blood and bone marrows remain unclear. The current case report describes the characteristic hematologic findings in patients with VEXAS, including macrocytic anemia, thrombocytopenia, marked hypercellular bone marrow with granulocytic hyperplasia, megaloblastic changes in erythroid precursors, and the absence of hematogones in addition to prominent vacuoles in myeloid and erythroid precursor cells. Characterizing the clinical and hematologic features helps to raise awareness and improve diagnosis of this novel, rare, but potentially underrecognized disease. Prompt diagnosis expands the general knowledgeable and understanding of this disease, and optimal management may prevent patients from developing complications related to this refractory inflammatory syndrome and improve the overall clinical outcome.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transtornos Mieloproliferativos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transtornos Mieloproliferativos / Neoplasias Idioma: En Ano de publicação: 2022 Tipo de documento: Article